Equities

Zynerba Pharmaceuticals Inc

Zynerba Pharmaceuticals Inc

Actions
  • Price (EUR)7.40
  • Today's Change0.35 / 4.96%
  • Shares traded0.00
  • 1 Year change15.09%
  • Beta4.7489
Data delayed at least 15 minutes, as of Oct 18 2019 07:12 BST.
More ▼

Profile data is unavailable for this security.

About the company

Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system. ZYN002 is in Phase II clinical development in patients with refractory epilepsy, in patients with osteoarthritis of the knee, as well as in patients with Fragile X syndrome. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through the skin and into the circulatory system through a patch. ZYN001 is targeting two pain indications, fibromyalgia and peripheral neuropathic pain.

  • Revenue in USD (TTM)86.00k
  • Net income in USD-35.88m
  • Incorporated2007
  • Employees25.00
  • Location
    Zynerba Pharmaceuticals Inc80 W. Lancaster Avenue, Suite 300DEVON 19333United StatesUSA
  • Phone+1 (484) 581-7505
  • Fax+1 (302) 655-5049
  • Websitehttp://zynerba.com/
More ▼
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.